-
Nirsevimab, sold
under the
brand name Beyfortus, is a
human recombinant monoclonal antibody with
activity against respiratory syncytial virus (RSV). It...
- GSK plc) and
Abrysvo (Pfizer). The
prophylactic use of
palivizumab or
nirsevimab (both are
monoclonal antibody treatments) can
prevent RSV
infection in...
- Merck, it is in a
phase III
trial as of 2023. It
works differently than
nirsevimab. Odumade,
Oludare A; van Haren,
Simon D; Angelidou,
Asimenia (15 August...
- them due to the
clear benefit that they have
shown in
clinical trials.
Nirsevimab, a
monoclonal antibody against RSV, is
approved by the FDA for all children...
- has also laid the
groundwork for
multiple patented therapies,
including Nirsevimab,
originally discovered by cell
biologist Hergen Spits.
Amsterdam UMC's...
-
Sotrovimab J06BD06
Regdanvimab J06BD07
Casirivimab and
imdevimab J06BD08
Nirsevimab J06BD09
Sipavibart Immune sera and
immunoglobulins for
veterinary use...
-
Stadium in Inglewood, California. July 17 – The FDA
approves the drug
Nirsevimab, also
known as Beyfortus,
which treats RSV in infants. July 18 – Michigan...
-
benralizumab (anti-IL-5R)
tralokinumab (anti-IL-13)
anifrolumab (anti-IFN-aR)
nirsevimab (anti-RSV) MedImmune, Inc. v. Genentech, Inc. "12
years on,
Astra draws...
-
squamous cell carcinoma, head and neck cancer,
nasopharyngeal cancer,
glioma Nirsevimab mab
human RSV
fusion glycoprotein respiratory syncytial virus Nivolumab...
- Exbivirumab§ Foravirumab§ Imdevimab† (+casirivimab) Libivirumab§
Maftivimab Nirsevimab†
Odesivimab Pemivibart Rafivirumab§ Regavirumab§
Regdanvimab Sevirumab†...
